TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

著者: Per Pfeiffer, Mette Yilmaz, Sören Möller, D. Zitnjak, Merete Krogh, Lone Nørgård Pétersen, Laurids Østergaard Poulsen, Stine Brændegaard Winther, Karina Gravgaard Thomsen, Camilla Qvortrup - The Lancet 2020 被引用: 231